高级检索
    徐开林, 朱锋, 王惊华. 有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究[J]. 循证医学, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
    引用本文: 徐开林, 朱锋, 王惊华. 有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究[J]. 循证医学, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
    shu
    XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
    Citation: XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
    shu

    有应用前景,但任重道远——评靶向CD3和CD123双特异性抗体flotetuzumab在复发/难治AML中的研究

    A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML

      摘要
      • HTML全文
      • 参考文献(4)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回